Hit by sur­prise set­back, As­traZeneca scram­bles to ex­plain why its two-in-one COPD in­haler was beat­en by GSK ri­val

As­traZeneca was ex­pect­ing a Phase II­Ib tri­al to put its two-in-one COPD in­haler on top of Glax­o­SmithK­line’s ri­val prod­uct. In­stead, it was hit by a trou­bling set­back.

The com­pa­ny re­port­ed that while Bevespi Aeros­phere (gly­copy­rro­ni­um/for­moterol fu­marate) didn’t do worse than GSK’s Anoro (ume­cli­dini­um/vi­lanterol) on peak forced ex­pi­ra­to­ry vol­ume in one sec­ond (FEV1), it didn’t do bet­ter ei­ther. And on trough FEV1, the oth­er co-pri­ma­ry end­point, As­traZeneca’s in­haler per­formed worse.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.